Key result
Early invasive strategy in NSTEMI may lose benefit as worsening renal function raises mortality risk.
Supports individualized decisions in NSTEMI with renal impairment; leaves open need for randomized trials to define optimal strategy.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Jin‐Sin Koh (2026) conducted a letter in NSTEMI with renal dysfunction. Early invasive strategy was evaluated. An early invasive strategy may not be universally beneficial in NSTEMI patients with impaired renal function, as worsening renal function modifies the risk-benefit balance and increases mortality risk.
Synapse has enriched 5 related papers. Consider them for comparative context: